MRK - Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED) | Benzinga
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer.
Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC).
The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant).
The study met its overall survival (OS) endpoint.
At a pre-specified interim analysis conducted by an independent ...